Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | LGMN | Q99538 | 1/20 | 0.51 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.50 |
| ▸ | MTOR | P42345 | 3/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14320480 | 0.92 | JAK2 (0.55) | AGXTLMNAJAK2LRRK2LGMN | |
| Aniline SCHEMBL28843768 | 0.91 | LMNA (0.53) | AGXTLMNAJAK2LRRK2LGMN | |
| SCHEMBL14320753 | 0.90 | AGXT (0.54) | AGXTLMNAJAK2LRRK2LGMN | |
| SCHEMBL224567 | 0.89 | ADRA2C (0.61) | AGXTLMNAJAK2LGMNKMO | |
| SCHEMBL6992774 | 0.89 | ADRA2C (0.61) | AGXTLMNAJAK2LGMNKMO | |
| SCHEMBL29371026 | 0.89 | ADRA2C (0.61) | AGXTLMNAJAK2LGMNKMO | |
| Hydrochloric Acid SCHEMBL14742169 | 0.87 | ADRA2C (0.59) | AGXTLMNAJAK2LGMNKMO | |
| SCHEMBL11210288 | 0.86 | LMNA (0.68) | AGXTLMNALRRK2KMOAR | |
| SCHEMBL27329825 | 0.81 | LMNA (0.71) | AGXTLMNALGMNKMOPIK3CA | |
| SCHEMBL15571300 | 0.80 | LMNA (0.55) | AGXTLMNAJAK2LGMNPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-9499535-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | AGXT 4050/4885LMNA 3015/4885JAK2 60/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | AGXT 4228/4885LMNA 3243/4885JAK2 48/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | AGXT 4050/4885LMNA 3015/4885JAK2 60/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | AGXT 4050/4885LMNA 3015/4885JAK2 60/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | AGXT 3880/4885LMNA 3020/4885JAK2 73/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | AGXT 3885/4885LMNA 3115/4885JAK2 37/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | AGXT 3885/4885LMNA 3115/4885JAK2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.